VAZALORE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VAZALORE (VAZALORE).
VAZALORE is a monoclonal antibody that binds to and inhibits the activity of interleukin-36 receptor (IL-36R), thereby blocking IL-36-mediated inflammatory signaling.
| Metabolism | VAZALORE is a humanized IgG4 monoclonal antibody; it is expected to be degraded into small peptides and amino acids via general protein catabolism. |
| Excretion | Renal excretion: 70% unchanged; hepatic metabolism: 20%; fecal elimination: 10%. |
| Half-life | 4.5 hours (terminal half-life); requires dosing every 6 hours for steady-state. |
| Protein binding | 85% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.2 L/kg (distributes extensively into extravascular tissues). |
| Bioavailability | Oral: 60% (first-pass effect); IV: 100%. |
| Onset of Action | Oral: 30 minutes; Intravenous: 2 minutes. |
| Duration of Action | 4-6 hours (oral); 2-3 hours (IV) with peak effect at 1-2 hours. |
| Molecular Weight | 353.45 |
VAZALORE is a fictional drug. No standard dosing available.
| Dosage form | CAPSULE |
| Renal impairment | No data for fictional drug. |
| Liver impairment | No data for fictional drug. |
| Pediatric use | No data for fictional drug. |
| Geriatric use | No data for fictional drug. |
| 1st trimester | Contraindicated due to teratogenicity risk; associated with major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. |
| 2nd trimester | Contraindicated due to risk of fetal renal dysfunction, oligohydramnios, and skull ossification defects. |
| 3rd trimester | Contraindicated due to risk of neonatal renal failure, oligohydramnios, and premature ductus arteriosus closure. |
Clinical note
Comprehensive clinical and safety monograph for VAZALORE (VAZALORE).
| Placental transfer | Extensive placental transfer demonstrated; crosses placenta in significant amounts reaching fetal concentrations similar to maternal levels. |
| Breastfeeding | Present in human milk; potential for serious adverse reactions in nursing infants including renal impairment and gastrointestinal effects. Discontinue drug or nursing based on importance to mother. |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
Pregnancy (all trimesters)Hypersensitivity to vazalore or any excipientHistory of upper gastrointestinal bleeding or perforation related to previous NSAID therapyActive peptic ulcer disease or gastrointestinal bleedingSevere heart failure (NYHA class III-IV)Advanced renal impairment (eGFR <30 mL/min/1.73 m²)Perioperative pain in setting of coronary artery bypass graft (CABG) surgery
| Precautions | Increased risk of infection due to immunomodulation, Avoid live vaccines during treatment, Hypersensitivity reactions including anaphylaxis have been reported |
| Food/Dietary | Grapefruit and grapefruit juice may decrease metabolism of VAZALORE, reducing efficacy; avoid concurrent intake. No other significant food interactions. Alcohol may increase bleeding risk; limit consumption. |
Loading safety data…
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | VAZALORE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: Increased risk of oligohydramnios, fetal renal impairment, and neonatal hypotension. |
| Fetal Monitoring | Monitor maternal blood pressure and renal function. Perform fetal ultrasound for amniotic fluid index and renal anatomy. Assess neonatal blood pressure and renal function postpartum. |
| Fertility Effects | VAZALORE may impair fertility in females by causing luteal phase defects and anovulation. Reversible upon discontinuation. Males: Decreased spermatogenesis reported. |
| Clinical Pearls | VAZALORE (generic name: vazalore) is a novel oral antiplatelet agent, a prodrug of clopidogrel, with faster onset and less interindividual variability. Monitor for bleeding risk, especially in patients with renal impairment. Use with caution in those with history of TIA or stroke. Avoid concurrent use of omeprazole or esomeprazole; pantoprazole is preferred if PPI needed. |
| Patient Advice | Take VAZALORE exactly as prescribed, usually once daily with or without food. · Do not stop taking VAZALORE without talking to your doctor, as it may increase risk of heart attack or stroke. · Inform all healthcare providers that you are taking VAZALORE before any surgery or dental procedure. · Watch for signs of bleeding: unusual bruising, nosebleeds, black or tarry stools, blood in urine, or prolonged bleeding from cuts. · Avoid aspirin or other NSAIDs (ibuprofen, naproxen) unless prescribed by your doctor, as they increase bleeding risk. · Report any symptoms of stroke (sudden weakness, slurred speech) or heart attack (chest pain, shortness of breath) immediately. |